Probiotix Health PLC New appointment (8537G)

TIDMPBX

RNS Number : 8537G

Probiotix Health PLC

24 July 2023

ProBiotix Health plc

( "ProBiotix" or the "Company")

New appointment

ProBiotix Health p lc (AQSE: PBX), a life sciences busi ness d eveloping probiotics to tackle cardiovascular disease and other lifestyle conditions, announces the appointment of Niels Peter Bak ("Niels Peter") as Technical Product Manager, effective from 1 September 2023.

Niels Peter has been brought on to the team as a pivotal part of executing the Company's strategy to focus the business towards finished supplement dosage formats. In line with the Company's defined strategic approach, Niels Peter will be heading up the product management function, with a specific focus on strengthening the infrastructure of ProBiotix, further accelerating product development and increasing the responsiveness to individual customer requirements. Niels Peter is a talented industry veteran with a proven track record in strategy execution, business to business product management, product development and technical marketing.

Niels Peter has almost 30 years' experience in international roles in the global probiotics space across a number of well-known organisations. He was an integral part of the team at Bifodan A/S, where he specialised in product portfolio development and operational product management and was instrumental in bringing the company's women's health probiotic product line onto the market. Following the acquisition of Bifodan A/S by Deerland, he assumed a managerial role involving probiotic solutions. Prior to this, Niels Peter worked at global bioscience company, Chr. Hansen, in the probiotics division across a number of technical product and marketing roles from 1989 until 2006.

Steen Andersen, CEO of ProBiotix Health plc commented: " Niels Peter's experience and track record of maintaining and expanding product portfolios to support growing sales, along with his network of industry contacts within the probiotics industry, will help us in our next phase of development. Niels Peter's appointment comes at an opportune time, now that we have established international sales and brand awareness of our award winning LP(LDL) (R) probiotic ingredient and our CholBiome(R) finished format product line. His appointment will allow us to further capitalise on our efforts so far, as we increase our access to the European and North American markets."

For further information, please contact:

 
 ProBiotix Health plc                             https://probiotixhealth-ir.com/ 
 Steen Andersen, Chief Executive                             Contact via Walbrook 
                                                                            below 
 
 Peterhouse Capital Ltd (AQSE Corporate Adviser                Tel: 020 7469 0930 
  and Broker) 
 Mark Anwyl 
 Duncan Vasey 
 
 Walbrook PR Ltd                                         probiotix@walbrookpr.com 
 Anna Dunphy                                                   Mob: 07876 741 001

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXBUGDRGDDDGXB

(END) Dow Jones Newswires

July 24, 2023 02:00 ET (06:00 GMT)

Probiotix Health (AQSE:PBX)
過去株価チャート
から 4 2024 まで 5 2024